NLRP3 and asthma: Besides, more detailed basic and clinical investigations through systemic inhibition studies such as knock-down or knock-out models are required to assess whether overexpression of TLR3/NLRP3/NF-κB/IRF3 signaling could reverse the protective effect of CAD on asthma.